Esperion Therapeutics, Inc. (LON:0IIM)

Market Cap	283.67M
Revenue (ttm)	220.44M
Net Income (ttm)	-64.74M
Shares Out	n/a
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,607
Average Volume	17,293
Open	1.885
Previous Close	1.875
Day's Range	1.815 - 1.885
52-Week Range	0.710 - 3.315
Beta	n/a
RSI	39.91
Earnings Date	Feb 25, 2025

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products als...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2008
• Employees: 240
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IIM

Financial Performance

In 2023, Esperion Therapeutics's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.

Financial numbers in USD